Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.
Hiroyuki KozaiHirokazu OginoAtsushi MitsuhashiNa Thi NguyenYuki TsukazakiYohei YabukiRyohiko OzakiHiroto YonedaSeidai SatoMasaki HanibuchiTsutomu ShinoharaHiroshi NokiharaYasuhiko NishiokaPublished in: Thoracic cancer (2023)
Our findings indicate that fluoropyrimidine can be an immunologically optimal partner of ICIs through the induction of ICD for thoracic malignancies.